Brief: Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
15/02/2024 12:47
Feb 15 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1
CLINICAL
TRIAL OF RP-1664
Source text for Eikon: ID:nBw5RzWdsa
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln